Recent Company News

• 06:25 AM ET May 08, 2025
  

  Recordati reports Q1 Adjusted net income €175.5M vs FactSet €130.7M [3 est, €128-135M]; confirms FY guidance (€53.20, +0.20)

• 01:20 PM ET Apr 28, 2025
  

  Recordati reports preliminary Q1 revenue €680M vs FactSet €675.2M [2 est, €674.4-676M]; provides long term guidance (€49.04, 0.00)

• 03:03 PM ET Apr 25, 2025
  

  FDA grants orphan drug designation to dinutuximab beta for Ewing sarcoma (€49.46, 0.00)

• 10:44 AM ET Apr 25, 2025
  

  EU's CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Cystadrops (€49.62, +0.40)

• 10:29 AM ET Apr 25, 2025
  

  EMA CHMP publishes summary of opinions for April meeting

• 02:12 AM ET Apr 16, 2025
  

  Recordati's Isturisa granted expanded indication for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome by FDA (€48.36, 0.00)

• 04:30 AM ET Apr 09, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 03:55 AM ET Apr 09, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (98 total)

• 10:02 PM ET Apr 08, 2025
  

  Follow-up: US President Donald Trump says the US will unveil "major" tariff on imports of pharmaceutical goods - NBC News

• 02:47 AM ET Mar 19, 2025
  

  Recordati upgraded to hold from sell at Deutsche Bank (€53.45, 0.00)